Aptus Pharma Limited (APPL) 52 Week High Streak: 2nd Straight Session
- September 18, 2026
- Posted by: Chaitanya Auti
- Category: News
Aptus Pharma Limited 52 Week High Streak has now extended to its second straight session, with the stock trading within 2% of its one-year peak across both days. According to latest Univest data, the cumulative move across the streak stands at 4.03%, while the stock traded at Rs 491.7 and touched a high of Rs 491.7. The pattern confirms repeated near-peak trading, but it does not point to a company-specific catalyst.
APPL was at Rs 482.1 in the previous session and opened at Rs 491.7, with the day’s low also at Rs 482.1. The company’s market capitalisation stands at Rs 843.27 crore. For readers tracking the Aptus Pharma Limited 52 Week High Streak, the important detail is the repeated stay near the upper end of the range over consecutive sessions rather than a one-time jump.
Aptus Pharma Limited (APPL) 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 491.7 |
| Previous Close | Rs 482.1 |
| Today's Move | +Rs 9.6 (+1.99%) |
| Open | Rs 491.7 |
| High | Rs 491.7 |
| Low | Rs 482.1 |
| Market Capitalisation | Rs 843.27 crore |
Aptus Pharma Limited (APPL) traded at Rs 491.7 versus the previous close of Rs 482.1, a rise of 1.99%. The stock opened at Rs 491.7, reached a high of Rs 491.7 and touched a low of Rs 482.1.
What the Repeated 52-Week Highs Show
The Aptus Pharma Limited 52 Week High Streak matters because it shows price behaviour over time, not just a brief spike. The latest Univest figures show the stock has remained within 2% of its 52-week high for a second straight session, with a cumulative streak gain of 4.03%. That makes the move notable for traders and market watchers who follow yearly-high names.
In practical terms, repeated trading near the top of the range suggests the market is willing to keep valuing the stock close to its recent ceiling. For a small-cap company in the Trading sector, that can draw added attention because such moves often bring more eyes to liquidity, valuation and business performance. The Aptus Pharma Limited 52 Week High Streak therefore serves as a useful marker of market interest, even without implying a fresh operating update or a new announcement.
Aptus Pharma Limited (APPL) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 843.27 crore |
| P/E Ratio | 182.53x |
| P/B Ratio | 25.07x |
| ROE | 30.48% |
| ROCE | 30.01% |
| EPS | Rs 2.69 |
| Book Value Per Share | Rs 19.61 |
| Dividend Yield | 0% |
Aptus Pharma Limited (APPL) fundamental metrics show P/E 182.53x, P/B 25.07x, ROE 30.48%, ROCE 30.01%. These figures provide context only and are not a buy or sell signal.
Aptus Pharma Limited has a market capitalisation of Rs 843.27 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 182.53x, P/B at 25.07x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 30.48% and ROCE of 30.01%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 2.69, book value per share of Rs 19.61, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 13.15x, median ROE of 4.1%, median ROCE of 5.96%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Trading |
| Industry | Trading |
| Benchmark Scope | same industry |
| Company P/E Ratio | 182.53x |
| Benchmark Median P/E | 13.15x |
| Benchmark Average P/E | 68.98x |
| Benchmark P/E Range | 0x to 3,234.04x |
| Company P/B Ratio | 25.07x |
| Benchmark Median P/B | 1.29x |
| Company ROE | 30.48% |
| Benchmark Median ROE | 4.1% |
| Company ROCE | 30.01% |
| Benchmark Median ROCE | 5.96% |
| Company Market Capitalisation | Rs 843.27 crore |
| Benchmark Median Market Cap | Rs 53.43 crore |
Aptus Pharma Limited (APPL) is classified under sector: Trading and industry: Trading.
Aptus Pharma Limited (APPL) has a P/E ratio of 182.53x, which is above the benchmark median of 13.15x, a difference of +1,288.06%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Aptus Pharma Limited (APPL) has a ROE of 30.48%, which is above the benchmark median of 4.1%, a difference of +643.41%. Aptus Pharma Limited (APPL) has a ROCE of 30.01%, which is above the benchmark median of 5.96%, a difference of +403.52%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Maxgrow India Ltd. | MAXGROW | 828.86 | 1.8 | 0.53 | 2.03 | 1.69 |
| Hexa Tradex Ltd. | HEXATRADEX | 878.11 | 0 | 0.18 | -0.19 | -0.12 |
| Vision Infra Equipment Solutions Ltd. | VIESL | 801.21 | 11.57 | 3.33 | 33.53 | 22.62 |
| TCC Concept Ltd. | TCC | 900.18 | 14.57 | 0.62 | 5.75 | 6.38 |
| The Yamuna Syndicate Ltd. | YSL | 774.86 | 8.59 | 0.61 | 4.07 | 4.15 |
Aptus Pharma Limited (APPL) has a P/E ratio of 182.53x compared with the displayed peer median of 8.59x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 30.48% compares with a peer median of 4.07% across the companies shown in the table. ROCE stood at 30.01% versus the displayed peer median of 4.15%, providing a capital-efficiency comparison. Aptus Pharma Limited (APPL) has a market capitalisation of Rs 843.27 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Aptus Pharma Limited
- It is trading within 2% of its 52-week high for a second straight session.
- The cumulative streak move stands at 4.03%.
- Market capitalisation is Rs 843.27 crore, which keeps it in the small-cap bracket.
- ROE of 30.48% and ROCE of 30.01% stand out versus industry medians.
- P/E and P/B remain much richer than the Trading sector benchmark.
About Aptus Pharma Limited
Aptus Pharma Limited, listed as APPL, operates in the Trading sector and the Trading industry. The company has a market capitalisation of Rs 843.27 crore and is being watched closely because its price is holding near the upper end of its recent range. The Aptus Pharma Limited 52 Week High Streak has helped bring additional focus to the stock, especially as investors compare valuation with profitability and sector peers.
The latest Univest data also shows a high P/E and P/B alongside strong return ratios. That combination often keeps a stock on watchlists when it trades near a yearly peak, since valuation and business quality become part of the same conversation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
What does the Aptus Pharma Limited 52 Week High Streak mean?
Ans. It means the stock has traded within 2% of its 52-week high for a second straight session. The focus is on repeated near-peak trading, which can highlight continued market interest.
What is the current price of Aptus Pharma Limited (APPL)?
Ans. According to latest Univest data, APPL traded at Rs 491.7. The stock was up 1.99% from the previous close of Rs 482.1, with the day’s high also at Rs 491.7.
How much has Aptus Pharma Limited moved across the streak?
Ans. The cumulative streak move stands at 4.03%, according to latest Univest data. That figure covers the repeated near-high trading across the two-session stretch and is distinct from the intraday move.
What is the market capitalisation of Aptus Pharma Limited?
Ans. Aptus Pharma Limited has a market capitalisation of Rs 843.27 crore. That places it in a smaller-company bracket, which often makes price moves more closely watched by market participants.
How does Aptus Pharma Limited compare on valuation?
Ans. The stock trades at a P/E ratio of 182.53x and a P/B ratio of 25.07x. Those levels are well above the same-industry benchmarks shown by Univest and deserve context-based reading.
What are the profitability metrics for Aptus Pharma Limited?
Ans. ROE stands at 30.48% and ROCE at 30.01%. These return ratios show a strong operating backdrop in the latest Univest figures, even though valuation remains elevated relative to peers.
Which sector does Aptus Pharma Limited belong to?
Ans. Aptus Pharma Limited is classified under the Trading sector and the Trading industry. That makes peer and benchmark comparison especially relevant when reading the Aptus Pharma Limited 52 Week High Streak.
Why are investors watching Aptus Pharma Limited now?
Ans. Investors are watching because the stock is holding close to its one-year high for a second straight session, while profitability ratios remain strong and valuation stays rich versus the sector benchmark.
Track Aptus Pharma Limited (APPL) Share Price on Univest
Use Aptus Pharma Limited (APPL) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.